{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-06T05:25:58.701Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-06. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-06. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-06, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"NTLA\",\n  \"company\": \"Intellia Therapeutics, Inc.\",\n  \"investigation_summary\": \"NTLA is a clinical-stage CRISPR gene editing biotech with two lead programs: lonvo-z for hereditary angioedema (HAE) and nex-z for ATTR amyloidosis. On April 27, 2026, the company announced that its Phase 3 HAELO trial met all primary endpoints with an 87% attack reduction vs placebo (p<0.0001), initiating a rolling BLA submission targeting completion in H2 2026 and potential US launch in H1 2027 — making this the first-ever positive Phase 3 readout for in vivo CRISPR gene editing. The stock trades ~52% below its 52-week high despite this landmark catalyst, with analyst consensus targets near $26 (vs ~$13-14 current price). Nex-z faces a partial FDA clinical hold on its ATTR-CM indication. ATM share dilution is ongoing; the company raised ~$33M in Q1 via at-the-market offerings. The stock has recovered strongly from sub-$9 levels but remains dramatically below peak, creating a potential asymmetric setup anchored by an unprecedented Phase 3 win and near-term regulatory catalyst.\",\n  \"verdict\": \"promising\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"long_stock\",\n    \"csp\",\n    \"cc\"\n  ],\n  \"business_snapshot\": \"Intellia is the leading clinical-stage CRISPR gene editing company with two in vivo genome editing programs in Phase 3 — both first-in-class for their indications. Lonvo-z (NTLA-2002) targets HAE, a rare genetic disease causing severe inflammatory attacks; HAELO Phase 3 demonstrated an 87% reduction in monthly attack rate vs placebo and met all secondary endpoints with no serious adverse events observed. The rolling BLA was initiated April 2026 and the company is preparing for a potential US launch in H1 2027, targeting a ~$500K+ addressable market (current LTP therapies cost $300-600K annually per patient). Nex-z (NTLA-2001) targets ATTR amyloidosis; the MAGNITUDE Phase 3 trial for ATTR-CM remains under FDA clinical hold following a Grade 4 liver transaminase elevation and patient death, though the ATTRv-PN arm (MAGNITUDE-2) had its IND hold lifted January 2026. With ~$376M in cash and runway into 2028 (per Q1 2026 filings), the company is funded through launch if approved. The Regeneron collaboration provides ~$15M/quarter in collaboration revenue supporting operations.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [\n        {\n          \"insider\": \"John M. Leonard\",\n          \"role\": \"President and CEO\",\n          \"amount_usd\": 0,\n          \"date\": \"2026-03-01\",\n          \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088269/xslF345X05/ownership.xml\"\n        }\n      ],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": 314365,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-08-06\",\n      \"recent_eps_surprise_pattern\": \"Positive EPS surprise in 4 consecutive quarters: Q3 2025 +7.8%, Q4 2025 +13.7%, Q1 2026 +9.8%. Loss narrowing trend consistent.\",\n      \"guidance_raise_in_last_90d\": false,\n      \"named_catalysts\": [\n        {\n          \"type\": \"product\",\n          \"description\": \"HAELO Phase 3 topline results: 87% attack reduction vs placebo (p<0.0001); all secondary endpoints met; favorable safety profile with no serious adverse events in lonvo-z arm. Rolling BLA initiated April 2026.\",\n          \"date_or_window\": \"April 27, 2026 — RESULTS ANNOUNCED\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526179401/d138980d8k.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"EAACI 2026 Late-Breaking Oral Presentation: Additional HAELO Phase 3 data for lonvo-z in HAE. June 2026.\",\n          \"date_or_window\": \"June 2026 (upcoming)\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/intellia-therapeutics-report-additional-phase-113000954.html?.tsrc=rss\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"Rolling BLA completion for lonvo-z targeting H2 2026; potential FDA approval and US commercial launch in H1 2027.\",\n          \"date_or_window\": \"H2 2026 — BLA completion; H1 2027 — Potential launch\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526179401/d138980d8k.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"FDA clinical hold on MAGNITUDE Phase 3 (nex-z, ATTR-CM) following Grade 4 liver transaminase elevation and patient death in October 2025. Hold on MAGNITUDE-2 (ATTRv-PN) lifted January 2026.\",\n          \"date_or_window\": \"Ongoing; engagement with FDA ongoing for MAGNITUDE\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm\"\n          ],\n          \"directional_bias\": \"bearish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": null,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": null,\n      \"fcf_yield_pct\": null,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"NTLA trades at ~$13.54 with analyst consensus price target of $26.63, implying roughly 97% upside to fair value if lonvo-z reaches approval and launch in 2027. The stock has recovered from sub-$9 levels (November 2025) but remains down ~52% from its 52-week high of $28.25. The dramatic underperformance relative to fundamental milestone achieved represents potential mispricing: the market appears to be discounting the HAE opportunity heavily due to commercial execution risk, payer negotiation uncertainty, and gene-editing novelty, while the first-ever positive Phase 3 CRISPR in vivo result has been insufficiently re-rated into shares.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": null,\n      \"net_debt_to_ebitda\": null,\n      \"balance_sheet_grade\": \"A\"\n    },\n    \"technical\": {\n      \"above_50dma\": false,\n      \"above_200dma\": true,\n      \"rsi_14\": 50.4,\n      \"macd_recent_bullish_cross\": true,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 13.54,\n    \"ytd_return_pct\": 46.7,\n    \"from_52w_high_pct\": -52.06\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-02-26\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm\",\n      \"key_takeaways\": [\n        \"FY2025 annual report; MAGNITUDE clinical hold disclosed (October 2025); HAELO enrollment completed September 2025; Regeneron collaboration extended April 2024 for $30M; Tech Square Lease signed February 2025 for ~125K sq ft at $108/sq ft with 12-year term\",\n        \"Cash and marketable securities of ~$375M as of December 31, 2025; runway into 2028 including proceeds from underwritten public offering in April 2026\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-05-11\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526215740/ntla-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026: collaboration revenue $15M; R&D spend $80.7M (down from $108.4M in Q1 2025); net loss $(96.2M) vs $(114.3M) year ago — narrowing losses; ATM offering raised ~$33.6M in Q1 2026\",\n        \"Cash and equivalents $134.7M + marketable securities $382.6M = total liquidity ~$517M as of March 31, 2026; shares outstanding grew from ~103.5M (Q1 2025) to ~120.4M (Q1 2026) — significant dilution\",\n        \"April 2026: positive Phase 3 HAELO topline results announced for lonvo-z\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-04-27\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526179401/d138980d8k.htm\",\n      \"key_takeaways\": [\n        \"HAELO Phase 3: PRIMARY ENDPOINT MET — 87% attack reduction vs placebo (p<0.0001); mean monthly attack rate 0.26 lonvo-z vs 2.10 placebo; all key secondary endpoints met with p<0.0001\",\n        \"62% of lonvo-z patients entirely attack-free and therapy-free for 6-month period vs 11% placebo; zero serious adverse events in lonvo-z arm during primary observation period\",\n        \"Rolling BLA initiated April 2026; completion targeted H2 2026; potential US launch H1 2027\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-04-30\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526197489/d308328d8k.htm\",\n      \"key_takeaways\": [\n        \"Underwritten public offering announced April 27, 2026 — dilution event noted; significant share count expansion post-Phase 3 data\"\n      ]\n    },\n    {\n      \"form\": \"4 (Form 4)\",\n      \"filed\": \"2026-03-01\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088269/xslF345X05/ownership.xml\",\n      \"key_takeaways\": [\n        \"CEO John M. Leonard received RSU grant of 156,400 shares vesting over time (March 1, 2026); stock option grant of 225,400 shares at $13.78 strike expiring February 2036; NOT open-market cash purchases — compensation-related transactions only\",\n        \"January 5, 2026: CEO sold 34,146 shares via mandatory sell-to-cover for RSU vesting tax withholding ($314K value)\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-06-18\",\n      \"2026-07-17\",\n      \"2026-09-18\",\n      \"2026-10-16\"\n    ],\n    \"iv_summary\": \"ATM IV ~93-96% across near-term expiries; elevated due to binary clinical/regulatory catalyst risk and upcoming EAACI data event (June 2026) and Q2 earnings (August 6, 2026). OI concentration in calls at strikes 18 (6077), 15 (2077), 19 (1941); puts at 14-15 (869, 911).\",\n    \"notable_skew_or_flow\": \"Bullish directional bias in near-term options flow (+$77K net call notional vs put); top OI on calls far above spot suggests market is hedging long equity positions or positioning for upside catalyst. Put/call ratio of 0.2 is strongly bullish at the aggregate level, though this partially reflects portfolio hedge activity.\"\n  },\n  \"competitive_landscape\": \"Intellia competes in rare disease CRISPR gene editing with Regeneron-partnered programs and standalone assets. Key competitors: Ionis Pharmaceuticals (antisense oligonucleotides for TTR amyloidosis), Alnylam (RNAi for ATTR/HFE — Onpattro, Amvuttra), CSL Behring/Pharming (HAE prophylactics like Haegarda), Takeda (TAK-101), and BioMarin (valrox for hemophilia A). For HAE specifically, the competitive set includes chronic prophylactic injectables/orals from these players; lonvo-z's differentiation is one-time curative potential. In ATTR amyloidosis, Ionis/Inotersen and Alnylam/Tegsedi represent established competition with chronic dosing; nex-z competes on a similar gene-editing curative thesis but faces greater safety uncertainty given the clinical hold. Intellia's competitive moat rests on its LNP-delivered CRISPR/Cas9 platform — first company to take in vivo gene editing into Phase 3.\",\n  \"key_risks\": [\n    \"FDA approval risk for lonvo-z BLA (H2 2026 submission; potential approval H1 2027); regulatory feedback could delay or require additional data\",\n    \"Commercial execution risk: rare disease specialty launch requires payer negotiations, specialty distribution, and physician adoption — NTLA has never commercialized a product\",\n    \"Nex-z MAGNITUDE clinical hold unresolved: FDA engagement ongoing; adverse outcome could eliminate ~50% of the addressable pipeline value (ATTR-CM market is larger than HAE)\",\n    \"ATM dilution ongoing: shares outstanding grew from ~103M to ~140M in 12 months, with more offerings likely before commercial revenue materializes\",\n    \"Patient death in MAGNITUDE trial (November 2025) and FDA clinical hold on ATTR-CM arm introduce regulatory overhang for the broader pipeline\",\n    \"Gene editing technology novelty creates payer uncertainty around pricing and reimbursement; CRISPR therapies have not yet established precedent pricing at scale in US market\",\n    \"Litigation: BlueAllele Corp. patent infringement suit ongoing; Gonzalez securities class action filed January 2025 alleging NTLA-3001 program misrepresentation (motion to dismiss pending); Aiello derivative suit over director compensation\",\n    \"Cash burn: Q1 2026 operating cash burn ~$117M; at current burn rate, existing liquidity is sufficient but significant dilution will likely continue\"\n  ],\n  \"what_the_market_might_be_missing\": \"The market may be underpricing lonvo-z's commercial potential by applying excessive discounting to a one-time curative CRISPR therapy. The Phase 3 HAELO results were unprecedented — the first-ever positive pivotal trial for in vivo CRISPR gene editing, with an 87% attack reduction and zero SAEs over 7+ months of follow-up. Market pricing appears anchored on payer pushback risk, commercial execution uncertainty, and historical skepticism toward gene-editing therapies — rather than a probability-weighted NPV calculation. With analyst consensus at $26 vs ~$13 current price, there is potential for re-rating as BLA progresses through FDA review in 2026-2027. Specifically: (1) the market may be ignoring the significant patient-reported outcome data showing near-universal willingness to switch to a one-time cure; (2) it may not be fully modeling the lifetime value given elimination of chronic prophylaxis costs ($300K-$600K/year x patient lifespan); (3) RMAT and PRIME regulatory designations suggest FDA/EMA recognition of transformative potential. The EAACI presentation in June 2026 could serve as a catalyst to begin re-rating shares before BLA completion.\",\n  \"anti_signals_present\": [\n    \"dilution\",\n    \"litigation\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"HAELO Phase 3 positive results — 8-K April 27, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526179401/d138980d8k.htm\"\n    },\n    {\n      \"label\": \"Q1 2026 10-Q filing\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526215740/ntla-20260331.htm\"\n    },\n    {\n      \"label\": \"FY2025 10-K annual report\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm\"\n    },\n    {\n      \"label\": \"EAACI presentation announcement June 1, 2026\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/intellia-therapeutics-report-additional-phase-113000954.html?.tsrc=rss\"\n    },\n    {\n      \"label\": \"H.C. Wainwright price target reiteration May 13, 2026\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/intellia-therapeutics-inc-ntla-buy-001621390.html?.tsrc=rss\"\n    },\n    {\n      \"label\": \"Q1 2026 earnings beat report May 12, 2026\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/ntla-q1-earnings-beat-estimates-154400643.html?.tsrc=rss\"\n    },\n    {\n      \"label\": \"Cathie Wood NTLA buying May 5, 2026\",\n      \"url\": \"https://www.barchart.com/story/news/1718399/intellia-therapeutics-stock-is-down-nearly-95-from-its-record-highs-but-cathie-wood-keeps-buying?.tsrc=rss\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-06T05:26:49.309Z",
      "raw_content": "<think>The dossier is for NTLA (Intellia Therapeutics, Inc.).\nScout verdict: \"promising\"\nMarket cap: Not explicitly given, but price is ~$13.54, shares outstanding ~120M-140M. Market cap is ~$1.6B - $1.9B. So it's \"asymmetric\" (≤ $5B).\nLet's score it.\n\nA. SMART-MONEY CLUSTER (max 25)\n- Insider purchases: CEO John M. Leonard received RSU grant (not open market). Material insider selling: $314K. Distinct buyers: 0.\n- 13F: \"pending — v2\" but mentions Cathie Wood buying (ARKK). Not a top-tier concentrated 13F initiation per se, but Cathie Wood is notable. However, the rubric says \"known concentrated 13F initiation/add (Berkshire, Pershing Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\". Cathie Wood/ARKK isn't explicitly listed, but I'll give 0 for this category due to lack of clear insider buying and no material smart money cluster data.\n- Score: 0\n\nB. OPTIONS FLOW / UOA (max 10)\n- ATM IV ~93-96% across near-term expiries. Elevated.\n- Bullish directional bias in near-term options flow (+$77K net call notional vs put).\n- Put/call ratio 0.2 is strongly bullish.\n- OI concentration in calls at 18, 15.\n- Score: 3 (bullish IV skew / flow, but elevated IV due to binary catalyst means it's not a traditional \"IV skew\" play, more of a binary event. I'll give 3 for flow bias.)\n\nC. CATALYST (max 25)\n- Earnings within 90 days: Aug 6, 2026. EPS surprise pattern positive for 4 quarters. (10 pts)\n- Product/Regulatory: HAELO Phase 3 met endpoints April 27, 2026. Rolling BLA initiated. EAACI June 2026. FDA approval potential H1 2027. (8 pts)\n- Guidance raise: false.\n- Sector tailwind: Not quantifiable.\n- Cap at 25. I'll give 18 (10 for earnings + 8 for regulatory/product catalyst). Actually, the rubric says: 10 for earnings + last 4 quarters EPS > 0. 8 for pending product/FDA. So 18.\n\nD. MISPRICING (max 15)\n- Forward P/E: null (biotech, pre-revenue).\n- EV/EBITDA: null.\n- FCF yield: null.\n- SOTP gap: ~97% upside to consensus target $26.63. But SOTP gap ≥ 25%? Analyst consensus implies ~97% upside. I'll give 5 pts for SOTP gap narrative, but it's based on analyst targets, not hard SOTP. I'll give 0 for mispricing metrics since they are null, but the narrative says 97% upside. I'll stick to 0 for the rubric's hard metrics, or maybe 5 for SOTP gap narrative? The rubric says \"5 pts: SOTP gap ≥ 25% (replaces one of the above)\". I'll give 5.\n\nE. QUALITY (max 15)\n- ROIC: null.\n- Gross margin: null.\n- Net debt/EBITDA: null. Balance sheet grade A.\n- Score: 0.\n\nF. MOMENTUM/TECHNICAL (max 10)\n- Above 50DMA: false.\n- Above 200DMA: true. (3 pts)\n- 12-1 momentum vs sector: null.\n- RSI 14: 50.4 (in 40-65 zone) -> 2 pts.\n- MACD bullish cross: true -> 1 pt.\n- Score: 6.\n\nTotal Score: 0 + 3 + 18 + 5 + 0 + 6 = 32.\nWait, let's re-evaluate carefully.\nSmart money: 0.\nOptions: 3.\nCatalyst: 18.\nMispricing: 5 (analyst upside ~97%).\nQuality: 0.\nTechnical: 6.\nTotal: 32.\n\nAnti-signals: \"dilution\", \"litigation\".\nThe rubric says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nDilution: ATM offering raised ~$33.6M in Q1 2026. Shares outstanding grew from ~103M to ~140M in 12 months. This is a significant dilution anti-signal.\nLitigation: BlueAllele patent suit, Gonzalez securities class action, Aiello derivative suit.\nThese are material anti-signals for a clinical-stage biotech. Dilution >10% of float is a hard gate in the rubric: \"Convertible/warrant overhang creating dilution > 10% of float\". Here it's ATM equity dilution, not convertible/warrant, but still dilution. The rubric says \"Customer concentration > 30%\", \"Convertible/warrant overhang creating dilution > 10% of float\". It doesn't explicitly list ATM equity dilution as a hard gate, but it's a strong negative.\nAlso, the score is 32, which is < 45. Threshold for asymmetric is <45 Skip.\nEven if I score it higher, the dilution and litigation anti-signals, plus the pre-revenue biotech status with no quality metrics, make it a skip.\nThe dossier itself says \"ATM share dilution is ongoing; the company raised ~$33M in Q1 via at-the-market offerings.\" and \"Cash burn: Q1 2026 operating cash burn ~$117M\".\nScore is well below 45. I will skip.\n\nLet's calculate score breakdown carefully to match rubric maxes:\nsmart_money: 0\noptions_flow: 3\ncatalyst: 18\nmispricing: 5\nquality: 0\ntechnical: 6\nComposite: 32\n\nReason: Score 32 (<45 threshold for asymmetric risk class). Material dilution from ongoing ATM offerings and unresolved clinical hold on the ATTR pipeline create unacceptable execution and capital structure risk for a pre-revenue biotech. The lack of insider buying, negative quality metrics, and high IV environment further diminish the risk/reward profile. Skip.\n\nCheck thresholds: ASYMMETRIC risk_class (< $5B). <45 Skip.\nMatches perfectly.\nI will output the skip JSON.\nDouble check the anti-signal gate: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nDilution: ATM equity dilution is ongoing and significant. It applies.\nLitigation: Ongoing patent and securities litigation. It applies.\nSkip is correct.\nOutput matches required format.\nAll dates in 2026 or later? Not applicable for skip, but I'll ensure no dates are written.\nReady. \nOutput matches exactly. \nProceed. \n{\n  \"skip\": true,\n  \"score\": 32,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 3,\n    \"catalyst\": 18,\n    \"mispricing\": 5,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Score 32 falls below the 45-point threshold for asymmetric risk class. Material ongoing ATM dilution and unresolved FDA clinical hold on the ATTR pipeline create unacceptable capital structure and execution risk for a pre-revenue biotech. Combined with zero insider buying, negative quality metrics, and elevated binary-event IV, the dossier lacks the hard fundamentals and risk/reward asymmetry required for publication.\"\n}\nWait, let's verify the score breakdown sums: 0+3+18+5+0+6 = 32. Correct.\nCheck rubric for catalyst: 10 pts for earnings within 90d + last 4 qtr EPS > 0. (8/8). 8 pts for pending product/FDA. Total 18. Cap 25. Correct.\nCheck technical: above 200DMA (3), RSI 40-65 (2), MACD bullish cross (1). Total 6. Correct.\nCheck mispricing: SOTP gap narrative implies ~97% upside to consensus, I gave 5. Correct.\nCheck options: bullish flow bias (3). Correct.\nAll good.\nOutput matches schema.\nProceeds. \nOne minor thing: The prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" I will explicitly mention this in the reason.\nReason: \"Score 32 falls below the 45-point threshold for asymmetric risk class. The anti-signal gates for dilution and litigation are active: ongoing ATM equity offerings have expanded the share count by ~35% in 12 months, and unresolved FDA clinical holds plus patent/securities litigation create material overhang. Combined with zero insider buying, negative quality metrics, and elevated binary-event IV, the dossier lacks the hard fundamentals and risk/reward asymmetry required for publication.\"\nMatches perfectly.\nOutput matches exactly.\nDone. \nProceeds. \n[Output Generation] -> JSON only. \nSelf-Correction/Verification during thought: \nWait, the prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will just state the skip reason clearly. The score is 32. The threshold is <45 Skip. So it's a skip regardless.\nI will format exactly as requested.\nAll good. \nOutput matches. \nProceeds. \n[Final Check of the Prompt]\n\"ONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that sub-object. Leave the others null/omitted.\" -> Not applicable for skip.\n\"IF YOU SKIP — output exactly: { \"skip\": true, \"score\": <0-100 composite>, \"score_breakdown\": {...}, \"reason\": \"...\" }\"\nMatches.\nDone. \nOutput Generation. \n```json\n{\n  \"skip\": true,\n  \"score\": 32,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 3,\n    \"catalyst\": 18,\n    \"mispricing\": 5,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Score 32 falls below the 45-point threshold for asymmetric risk class. The active anti-signal gates for dilution and litigation are material: ongoing ATM equity offerings expanded the share count by ~35% in 12 months, and unresolved FDA clinical holds plus patent/securities litigation create significant overhang. Combined with zero insider buying, negative quality metrics, and elevated binary-event IV, the dossier lacks the hard fundamentals and risk/reward asymmetry required for publication.\"\n}\n```\nMatches requirements. No extra text. Valid JSON. Dates not needed. Score breakdown matches rubric. Reason addresses gates and threshold. Ready. \nProceeds. \n[Output Generation] (matches the final block)\nNote: I will ensure the JSON is strictly valid and contains no markdown fences as per \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\"\nDone. \nProceeds. \n(Self-Correction/Refinement during thought)\nWait, the prompt says \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\"\nI will output raw JSON.\nCheck score breakdown keys: \"smart_money\", \"options_flow\", \"catalyst\", \"mispricing\", \"quality\", \"technical\". Matches exactly.\nCheck reason length: 1-2 sentences? The prompt says \"1-2 sentences why this dossier doesn't support a thesis.\" I'll condense it to strictly 1-2 sentences.\nCondensed reason: \"Score 32 falls below the 45-point threshold for asymmetric risk class. Active anti-signal gates for dilution and litigation are material, and combined with zero insider buying, negative quality metrics, and elevated binary-event IV, the dossier lacks the fundamental backing and risk/reward asymmetry required for publication.\" (2 sentences)\nPerfect.\nOutput matches.\nProceeds. \n[Final Output Generation] -> Raw JSON. \n(Note: I will carefully verify the JSON syntax.)\nAll good. \nProceeds. \n[Output] -> *Self-Correction/Verification during generation prep*: \nThe prompt says: \"IF YOU SKIP — output exactly: { \"skip\": true, ... }\"\nI will output exactly that.\nDone. \n[Output Generation]\n```json\n{\n  \"skip\": true,\n  \"score\": 32,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 3,\n    \"catalyst\": 18,\n    \"mispricing\": 5,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Score 32 falls below the 45-point threshold for asymmetric risk class. Active anti-signal gates for dilution and litigation are material, and combined with zero insider buying, negative quality metrics, and elevated binary-event IV, the dossier lacks the fundamental backing and risk/reward asymmetry required for publication.\"\n}\n```\nWait, the prompt says \"No surrounding prose, no markdown fences.\" I will remove the ```json and ``` markers.\nProceeds. \nOutput matches exactly. \nDone. \n[Final Check]\nScore: 32\nBreakdown keys match rubric.\nReason is 2 sentences.\nRisk class: asymmetric (market cap ~$1.6B < $5B). Threshold <45 Skip. Correct.\nAnti-signals addressed. Correct.\nReady. \nOutput matches. \n[Proceeds]\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 32,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 3,\n    \"catalyst\": 18,\n    \"mispricing\": 5,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Score 32 falls below the 45-point threshold for asymmetric risk class. Active anti-signal gates for dilution and litigation are material, and combined with zero insider buying, negative quality metrics, and elevated binary-event IV, the dossier lacks the fundamental backing and risk/reward asymmetry required for publication.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 32,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 3,\n    \"catalyst\": 18,\n    \"mispricing\": 5,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Score 32 falls below the 45-point threshold for asymmetric risk class. Active anti-signal gates for dilution and litigation are material, and combined with zero insider buying, negative quality metrics, and elevated binary-event IV, the dossier lacks the fundamental backing and risk/reward asymmetry required for publication.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 32,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 3,\n    \"catalyst\": 18,\n    \"mispricing\": 5,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Score 32 falls below the 45-point threshold for asymmetric risk class. Active anti-signal gates for dilution and litigation are material, and combined with zero insider buying, negative quality metrics, and elevated binary-event IV, the dossier lacks the fundamental backing and risk/reward asymmetry required for publication.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 50608,
  "stop_reason": "stop",
  "completed_at": "2026-06-06T05:26:49.309Z"
}